LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global intrathecal pumps market to grow at a CAGR of more than 4% during the forecast period, according to their latest report.
The research study covers the present scenario and growth prospects of the global intrathecal pumps market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of intrathecal pumps.
According to Barath Palada, a lead analyst at Technavio for medical devices research, “Around 1.5 billion people are reported to have chronic pain, and the prevalence rate of chronic pain is expected to increase over the years, which simultaneously drives the intrathecal pumps delivery therapy. In terms of geography, the Americas dominated the market, with the US being the highest contributor.”
Technavio healthcare and life sciences analysts highlight the following four factors that are contributing to the growth of the global intrathecal pumps market:
- Increased prevalence of chronic pain
- Increased need for better therapies for cancer pain management
- Favorable insurance programs
- Cost-effective nature of intrathecal pumps therapy
Increased prevalence of chronic pain
Chronic pain is an enormous health problem worldwide. About 20% of adults are diagnosed with chronic pain worldwide. Pain is the most feared symptom in individuals diagnosed with cancer. More than 50% of individuals with cancer report pain as the main symptom at the time of diagnosis and early in the course of cancer. Although there are several treatments available for pain management, in most cases, opiates are administered through the intrathecal drug delivery system for cancer-related and non-malignant pain.
Some of the other pain conditions include chronic pancreatitis, neuropathic pain, spinal cord injury pain, diffuse pain, central pain, arachnoiditis, brachial plexus neuritis, post stroke pain, and peripheral neuropathy. Individuals who cannot tolerate side effects of a higher dosage of oral pain medications are the potential users of intrathecal pumps.
Increased need for better therapies for cancer pain management
There are several treatments available for cancer pain management such as oral non-steroidal anti-inflammatory drugs, neuropathic pain medications, oral opioid analgesics, parenteral opioids, peripheral nerve blocks, neurolysis, spinal cord stimulation, local anesthetic injections, continuous epidural analgesia, and intrathecal pumps. However, intrathecal opioids are found to be more superior to oral delivery and non-malignant pain. As the medication is delivered directly into the cerebrospinal fluid (CSF) in the intrathecal space, the dosage required for this therapy is less compared to other treatments such as oral or intravenous. With a smaller dosage of the drug and a more direct route to the pain processing center in the spinal cord, the individual experiences superior analgesia with minor side effects such as nausea, erythema, pruritus, flushing, and constipation. The success rate of intrathecal drug delivery was 85% compared to 71% in conventional drug delivery. The intrathecal pumps are serving as a better alternative for the other pain management therapies.
Favorable insurance programs
The healthcare insurance programs such as Medicare are driving the market. Several indications for treatment using infusion pumps are covered under this program. Morphine infusion through an external infusion pump is covered when used in the treatment of intractable pain due to cancer (in an inpatient or outpatient setting, including a hospice). “An implantable infusion pump is covered under this program when used to administer anti-spasmodic drugs such as baclofen intrathecally to treat chronic intractable spasticity in people who have proven unresponsive to less invasive medical therapy. It also covers opioid drugs for the treatment of chronic intractable pain,” adds Barath.
Cost-effective nature of intrathecal pumps therapy
Intrathecal therapy is considered to be a cost-effective treatment compared to conventional treatment options. An individual diagnosed with chronic pain often visits the emergency room, multiple doctor consultations, and various investigations. Despite the high cost of intrathecal equipment, the therapy reduces the need for visits to the emergency department, frequent hospital visits, and hospitalization. There is a range of full economic evaluations, which investigated the costs and benefits associated with the use of intrathecal morphine for chronic non-malignant pain. Intrathecal drug delivery has also been studied to be a cost-effective alternative to systemic, intravenous, or external infusion devices for individuals with cancer who require pain management for three months or more.
Browse Related Reports:
- Global Pain Management Drugs Market 2016-2020
- Infusion Systems Market in Japan 2016-2020
- Global Cancer Pain Therapeutics Market 2015-2019
Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio’s reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
